|
|
Health Care Providers |
Indications
to physicians to order the fatty acid profile EFA-SRä
|
Edward Siguel, MD PhD |
|
Fatty Acid Laboratory c/o Dr. Siguel REF: FATTY ACID ANALYSIS/ FATTY ACID PROFILES Dear Colleague: I hope that you will consider analyzing plasma fatty acids in patients at risk for nutritional deficiencies and in those suffering from disorders linked with fatty acid abnormalities such as coronary artery disease, diabetes mellitus, and hypertension. Based on my clinical experience and research, it is my opinion that an assessment of fatty acid abnormalities and of EFA status provides useful and practical information in the evaluation and monitoring of patients likely to suffer from fatty acid abnormalities. For the past several years, I have been evaluating fatty acid profiles in TPN patients and patients with chronic intestinal disorders, obesity, neurological disease, cystic fibrosis, and other conditions. (For a brief description of our results, see Original articles and Credentials) I found that significant abnormalities of fatty acid metabolism in many patients have been overlooked by traditional methods of laboratory testing. Many of my patients have difficulties in absorbing or tolerating lipids enterally and some cannot tolerate parenteral lipids. I have found that fatty acid analysis allows me to determine the smallest quantity of lipids necessary to maintain EFA status and adequate overall nutrition in these patients. Plasma fatty acids are established risk factors for cardiovascular disease, diabetes, hypertension, hyperlipidemia, and other disorders. These conditions can now be treated with diets rich in specific fatty acids (but not high in total fat or calories). With more than 10 years experience in the diagnosis of disorders of fatty acid metabolism, we are available to fulfill a clinical need to assess fatty acid status. Using High Resolution Capillary Column Gas Liquid Chromatography (GLC), our method quantifies plasma levels of the major fatty acids, including the essential fatty acids (EFAs), linoleic and linolenic acid. The fatty acid profile EFA Status Report (EFA-SRÔ) documents fatty acids of chain length C14 up to C24, including the EFAs, arachidonic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), the eicosanoid precursors, and key trans fatty acids. Our results have been published in peer review medical journals and our methods, based upon Patent No. 5075101, were used to analyze samples from the Framingham Heart Study. The profile EFA-SRÔ will assist you in diagnosing abnormalities of fatty acid metabolism and in optimizing nutritional treatment. With the aid of the profile EFA-SRÔ, you may improve management of altered plasma lipid levels and hypertension. The profile EFA-SRÔ will also assist in monitoring blood coagulation, in preventing cardiovascular disease and the complications of diabetes mellitus, and in improving the overall health status of your patients. Not only do our reports identify the amounts of each fatty acid, but also they include an interpretative diagnosis together with treatment suggestions. Because EFAs are essential nutrients, deficiencies diagnosed by the profile EFA-SRÔ may be corrected with enteral or parenteral lipid or oil supplements. We routinely analyze whole plasma, but we can also analyze other tissues. If you are interested in collaborative research, please FAX/mail a brief description and a researcher will contact you at your convenience. We can partially subsidize collaborative research. Prices depend on the analyses requested, the type of sample, and whether it is for clinical or research purposes. Sincerely, |
Read the book "EFAs in Health and Disease" and Dr. Siguel's other publications for use of the test, medical necessity, prototype letters for patients, etc.
|
By
reading this web site, you agree to read & comply with the following
instructions: You agree to pay us $300 for each unsolicited communication to sell us unsolicited products/services (by e-mail, mail, phone, etc.). Read details. |
|
|
© 1998 Edward
Siguel. All rights reserved |
modified 1/15/00 |